France · Delayed Price · Currency is EUR bioMérieux Statistics
Total Valuation
bioMérieux has a market cap or net worth of EUR 10.70 billion. The enterprise value is 10.59 billion.
| Market Cap | 10.70B |
| Enterprise Value | 10.59B |
Important Dates
The last earnings date was Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | Jun 9, 2026 |
Share Statistics
bioMérieux has 117.95 million shares outstanding. The number of shares has increased by 0.06% in one year.
| Current Share Class | 117.95M |
| Shares Outstanding | 117.95M |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 17.51% |
| Float | 44.73M |
Valuation Ratios
The trailing PE ratio is 27.16 and the forward PE ratio is 19.15. bioMérieux's PEG ratio is 2.20.
| PE Ratio | 27.16 |
| Forward PE | 19.15 |
| PS Ratio | 2.63 |
| PB Ratio | 2.61 |
| P/TBV Ratio | 3.60 |
| P/FCF Ratio | 23.61 |
| P/OCF Ratio | 13.57 |
| PEG Ratio | 2.20 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.07, with an EV/FCF ratio of 23.38.
| EV / Earnings | 26.65 |
| EV / Sales | 2.60 |
| EV / EBITDA | 9.07 |
| EV / EBIT | 15.25 |
| EV / FCF | 23.38 |
Financial Position
The company has a current ratio of 2.39, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.39 |
| Quick Ratio | 1.42 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.40 |
| Debt / FCF | 1.02 |
| Interest Coverage | 43.97 |
Financial Efficiency
Return on equity (ROE) is 9.54% and return on invested capital (ROIC) is 13.12%.
| Return on Equity (ROE) | 9.54% |
| Return on Assets (ROA) | 7.66% |
| Return on Invested Capital (ROIC) | 13.12% |
| Return on Capital Employed (ROCE) | 15.41% |
| Weighted Average Cost of Capital (WACC) | 7.66% |
| Revenue Per Employee | 281,628 |
| Profits Per Employee | 27,507 |
| Employee Count | 14,754 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.76 |
Taxes
In the past 12 months, bioMérieux has paid 128.80 million in taxes.
| Income Tax | 128.80M |
| Effective Tax Rate | 24.50% |
Stock Price Statistics
The stock price has decreased by -21.61% in the last 52 weeks. The beta is 0.66, so bioMérieux's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | -21.61% |
| 50-Day Moving Average | 97.70 |
| 200-Day Moving Average | 110.80 |
| Relative Strength Index (RSI) | 30.15 |
| Average Volume (20 Days) | 138,722 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, bioMérieux had revenue of EUR 4.07 billion and earned 397.50 million in profits. Earnings per share was 3.34.
| Revenue | 4.07B |
| Gross Profit | 2.31B |
| Operating Income | 694.80M |
| Pretax Income | 525.70M |
| Net Income | 397.50M |
| EBITDA | 1.13B |
| EBIT | 694.80M |
| Earnings Per Share (EPS) | 3.34 |
Balance Sheet
The company has 569.80 million in cash and 461.40 million in debt, with a net cash position of 108.40 million or 0.92 per share.
| Cash & Cash Equivalents | 569.80M |
| Total Debt | 461.40M |
| Net Cash | 108.40M |
| Net Cash Per Share | 0.92 |
| Equity (Book Value) | 4.11B |
| Book Value Per Share | 34.77 |
| Working Capital | 1.48B |
Cash Flow
In the last 12 months, operating cash flow was 788.40 million and capital expenditures -335.30 million, giving a free cash flow of 453.10 million.
| Operating Cash Flow | 788.40M |
| Capital Expenditures | -335.30M |
| Depreciation & Amortization | 434.90M |
| Net Borrowing | -29.60M |
| Free Cash Flow | 453.10M |
| FCF Per Share | 3.84 |
Margins
Gross margin is 56.73%, with operating and profit margins of 17.07% and 9.77%.
| Gross Margin | 56.73% |
| Operating Margin | 17.07% |
| Pretax Margin | 12.92% |
| Profit Margin | 9.77% |
| EBITDA Margin | 27.76% |
| EBIT Margin | 17.07% |
| FCF Margin | 11.13% |
Dividends & Yields
This stock pays an annual dividend of 0.98, which amounts to a dividend yield of 1.06%.
| Dividend Per Share | 0.98 |
| Dividend Yield | 1.06% |
| Dividend Growth (YoY) | 8.89% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 26.69% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 1.00% |
| Earnings Yield | 3.72% |
| FCF Yield | 4.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 20, 2017. It was a forward split with a ratio of 3.
| Last Split Date | Sep 20, 2017 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
bioMérieux has an Altman Z-Score of 7.11 and a Piotroski F-Score of 7.
| Altman Z-Score | 7.11 |
| Piotroski F-Score | 7 |